The study builds on earlier work by the same group, which had identified SARS-CoV-2 antigens showing both sequence and conformational homology to tumor-associated antigens, the molecular flags that tumors display on their surfaces and that the immune system can, in principle, attack. Cross-reactive T cells had already been detected in people who had either been infected with SARS-CoV-2 or vaccinated with the BNT162b2 mRNA vaccine. What remained unknown was the fine structure of that cross-reactivity: which T cell receptor genes were involved, what the hypervariable recognition loops looked like, and whether the same receptor architectures could be elicited by both the viral and the tumor-derived peptide. The new study set out to answer those questions directly.

To do so, the researchers selected a matched pair of epitopes presented by the same class of major histocompatibility complex molecules. The viral peptide, LLLDDFVEI, comes from a SARS-CoV-2 antigen, while its tumor counterpart, LLLDDLLVS, is derived from PRDX5, a tumor-associated antigen. The two nine-amino-acid sequences differ by only two residues, and both substitutions are conservative, meaning the overall shape and chemical character of the peptides are largely preserved. When processed and displayed on the cell surface in the peptide–MHC complex, the two epitopes present a sufficiently similar molecular surface that a single T cell receptor can plausibly engage both — the defining premise of molecular mimicry.

The experimental design was deliberately simple and controlled. Peripheral blood mononuclear cells were obtained from five healthy donors and cultured in the laboratory for ten days, during which the cells were stimulated every three days with 10 micrograms of one or the other of the two peptides. This ex vivo priming allowed rare cross-reactive T cells to expand to numbers that could be reliably detected and characterized. After the stimulation period, the researchers performed single-cell RNA sequencing paired with T cell receptor sequencing, a technique that captures both the transcriptomic identity of each cell and the full nucleotide sequence of its receptor’s alpha and beta chains, including the crucial CDR3 regions that make direct contact with the peptide–MHC complex.

The results, focused on CD8-positive effector T cells, revealed a striking pattern. In each donor, treatment with either epitope amplified or newly induced a small, reproducible set of TRAV and TRBV gene segments — the variable regions of the receptor’s alpha and beta chains — together with characteristic CDR3α and CDR3β amino acid motifs. Critically, the very same clonotypes appeared in both stimulation conditions: T cells expanded by the viral peptide carried the same receptor signatures as those expanded by the tumor peptide. These signatures were strictly individual, differing from donor to donor, and none of the identified motifs matched any entry in publicly available T cell receptor repositories, underscoring how personal the anti-viral and, by extension, the cross-reactive anti-tumor repertoire can be.

The cross-reactive clones were not confined to the effector compartment. The researchers found the identical clonotypes within the CD8-positive proliferating subset, indicating that both epitopes drove the same cells into a highly activated, dividing state. In immunological terms, this plasticity matters: it suggests that exposure to the viral epitope does not merely expand a narrow, terminally differentiated population but recruits versatile effector cells capable of further proliferation and functional diversification — properties desirable in a vaccine-elicited response intended to attack tumor cells presenting the mimic antigen in vivo.

To test whether the shared clonotypes reflected genuine structural cross-recognition rather than coincidental co-expansion, the team performed conformational prediction analyses of the peptide–MHC–TCR complexes. The modeled structures showed a perfect structural overlap between complexes built on the viral epitope and those built on the tumor epitope. In other words, when the same receptor docks onto either peptide presented by MHC, the geometry of the interaction is essentially indistinguishable. This structural convergence provides a mechanistic explanation for the functional cross-reaction observed in the cell cultures and elevates the finding from a correlational observation to a validated molecular event.

The authors emphasize the functional significance of the result in light of a well-known feature of T cell biology: degeneracy. A single T cell receptor can often recognize multiple different peptides, and a single epitope can be recognized by many different receptors. Given this inherent promiscuity, finding identical CDR3αβ motifs elicited by two homologous but non-identical epitopes is, as the researchers describe it, of the highest functional relevance. It demonstrates that the mimicry between the SARS-CoV-2 peptide and the PRDX5-derived tumor peptide is tight enough to select for the same receptor solutions across independent stimulation conditions and across genetically distinct donors’ repertoires.

The translational implication is the most consequential part of the work. Tumor-associated antigens are self antigens, and the immune system is generally tolerant of them, which has long hampered therapeutic cancer vaccines: self-derived peptides tend to be weak immunogens that expand low-affinity or exhausted T cells, if they expand anything at all. Microbial epitopes, by contrast, are foreign, and the immune system responds to them vigorously. The study’s results provide, for the first time, a clear experimental validation that microbial epitopes mimicking tumor-associated antigens can be used to develop off-the-shelf preventive or therapeutic vaccine formulations. A vaccine built on a viral mimic would exploit the immune system’s readiness to mount strong responses against non-self sequences while redirecting the resulting effector cells, through cross-reactivity, against tumor cells displaying the homologous self antigen.

Several caveats and open questions remain before such a strategy reaches the clinic. The study involved five healthy donors and a single epitope pair, so the breadth of the mimicry effect across other tumor antigens, HLA backgrounds, and patient populations will need to be established. Whether vaccine-elicited cross-reactive T cells can actually infiltrate tumors and mediate clinically meaningful anti-tumor activity in vivo is the decisive next test, and the risk that broadly cross-reactive responses could target healthy tissues expressing PRDX5 must be carefully evaluated. The work was funded by the Italian Ministry of Health through institutional research programs and a PNRR project on molecular mimicry to improve liver cancer immunotherapy, signaling that hepatocellular carcinoma is one intended application. Even with those qualifications, the study marks a milestone: it converts molecular mimicry from an epidemiological curiosity — the observation that some infections correlate with altered cancer risk — into a precisely characterized receptor-level mechanism that can be engineered on purpose. If follow-up studies confirm that viral-mimic vaccines can reliably expand functional, tumor-directed CD8 T cells, the pandemic coronavirus that reshaped global health may also leave behind an unexpected gift for oncology.

Subject of Research: Cross-reactivity between SARS-CoV-2-specific T cells and tumor-associated antigens via molecular mimicry

Article Title: SARS-CoV-2-specific T cells cross-react with tumor-associated antigens via molecular mimicry

Article References: Ragone, C., Mauriello, A., Cavalluzzo, B., Mangano, S., Cembrola, B., Ciotola, N., Tagliamonte, M., & Buonaguro, L. (2026). SARS-CoV-2-specific T cells cross-react with tumor-associated antigens via molecular mimicry. Journal of Translational Medicine, 24(1), Article 1179. https://doi.org/10.1186/s12967-026-08905-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08905-5

Keywords: SARS-CoV-2, molecular mimicry, tumor-associated antigens, T cell receptor, cross-reactivity, cancer vaccine, CD8 T cells, single-cell RNA sequencing, PRDX5, immunotherapy, epitopes, Journal of Translational Medicine

Central to T cell recognition of tumors are two primary classes of antigens. Tumor-specific neoantigens arise from somatic mutations unique to cancer cells, exhibiting high immunogenicity and minimal expression in normal tissues. Such neoantigens offer exquisite specificity, reducing the risk of off-tumor effects. Conversely, tumor-associated antigens, while not exclusive to malignant cells, are often overexpressed in tumors and serve as additional targets to mobilize T cell cytotoxicity. This dual targeting strategy underscores the complexity of immune surveillance within heterogeneous tumor ecosystems.

Despite the potent capabilities of T cells, tumors have evolved sophisticated mechanisms to evade immune detection and destruction. Among these, the induction of T cell exhaustion within the immunosuppressive tumor microenvironment (TME) significantly impairs the effector functions of infiltrating lymphocytes. This exhaustion is characterized by sustained expression of inhibitory receptors and diminished cytokine production, effectively blunting the anti-tumor immune response and fostering tumor progression under an immunologically suppressive milieu.

Moreover, tumors can undergo immunoediting, a dynamic process wherein cancer cells lose or alter their antigenic profiles to escape T cell recognition. This antigenic plasticity poses a substantial barrier to effective immunotherapy, necessitating strategies that address tumor heterogeneity and adaptability. Physical barriers within the TME, including aberrant vasculature and stromal components, further obstruct T cell infiltration and limit their capacity to exert cytotoxic effects at tumor sites.

Modern immunotherapeutic approaches leverage the diverse functionalities of T cells to circumvent tumor evasion. Antibody-based therapies, such as immune checkpoint inhibitors, alleviate inhibitory signals like PD-1/PD-L1 and CTLA-4 pathways, reinvigorating exhausted T cells. Bispecific T cell engagers (BiTEs) bridge T cells to tumor cells, facilitating direct cytotoxic engagement. These modalities have revolutionized treatment paradigms, achieving remarkable clinical responses in several cancer types.

Adoptive Cell Transfer (ACT) represents another therapeutic frontier in which autologous or allogeneic T cells are expanded or genetically engineered ex vivo and then infused back into patients. Tumor-Infiltrating Lymphocyte (TIL) therapy involves isolating and expanding naturally occurring tumor-specific T cells. Genetically modified therapies, including Chimeric Antigen Receptor (CAR) T cells and T Cell Receptor-engineered (TCR-T) cells, enhance recognition capabilities against specific tumor antigens, opening new avenues for hematologic and solid tumor treatment.

Cancer vaccines are designed to prime the immune system by presenting tumor antigens, inducing robust, antigen-specific T cell responses. These vaccines serve as both prophylactic and therapeutic tools, aiming to generate durable immunity against existing tumors or prevent tumor recurrence. Despite their promise, the immunosuppressive TME and antigenic variability continue to challenge vaccine efficacy in clinical contexts.

Professor Tao Dong emphasizes the necessity of combination therapies that integrate these distinct immunotherapeutic modalities. Such regimens are designed to conduct a multifaceted assault on cancer—overcoming antigen escape, reversing T cell exhaustion, and dismantling the physical and immunological barriers of the TME. The orchestration of these therapies holds the key to overcoming the limitations of monotherapies and improving patient outcomes comprehensively.

Cutting-edge research efforts are focused on two critical axes that could revolutionize T cell immunotherapy. First, the identification and cataloging of precise tumor antigens, alongside sophisticated T cell receptor (TCR) libraries, aim to tailor treatments uniquely suited to individual tumor antigen landscapes. Second, unraveling the nuanced biology of T cell subsets and their functional states promises to yield biomarkers for optimizing patient selection and predicting therapeutic responses, thus personalizing immunotherapy at an unprecedented scale.

This comprehensive understanding of T cell-mediated immunity and the multifarious avenues of immunotherapeutic intervention form a robust framework for pioneering more effective, resilient cancer treatments. Researchers and clinicians are poised to translate these insights into clinical success, addressing enduring challenges such as tumor heterogeneity, immune suppression, and therapy-induced toxicities.

As the field advances, technological innovations including single-cell omics and spatial transcriptomics are refining our ability to dissect T cell-tumor interactions in situ, providing granular insights into immune evasion and therapeutic resistance. These precision tools facilitate the rational design of next-generation immunotherapies, with the potential to unlock enduring remission and possibly cure for diverse malignancies.

In sum, leveraging T cells for cancer immunotherapy embodies a paradigm shift, harnessing the specificity, adaptability, and potency of adaptive immunity. The convergence of molecular understanding, engineering prowess, and clinical acumen heralds a new era in oncology—one where immune cells are not just defenders but powerful allies in the quest to conquer cancer.

Subject of Research: Not applicable

Article Title: Leveraging T cells for cancer immunotherapy

News Publication Date: 21-Oct-2025

References: DOI: 10.1007/s44466-025-00007-z

Image Credits: Professor Tao Dong Team, University of Oxford, Oxford, UK

Keywords: Cancer immunotherapy, T lymphocytes, Immunity, Tumor microenvironments, Antigens, Neoantigens, Cancer vaccines, Cancer treatments, Biomarkers, Cell biology